Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats
The present study was undertaken to determine the effect of pioglitazone (3, 10 and 30 mg/kg p.o.), an insulin sensitizer, on glucose intolerance in high fat diet- (HFD) fed rats (a nongenetic model of insulin resistance). In addition, the effect of pioglitazone (3, 10 and 30 mg/kg p.o.) on diet-ind...
Saved in:
Published in | Methods and findings in experimental and clinical pharmacology Vol. 26; no. 5; p. 327 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Spain
01.06.2004
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The present study was undertaken to determine the effect of pioglitazone (3, 10 and 30 mg/kg p.o.), an insulin sensitizer, on glucose intolerance in high fat diet- (HFD) fed rats (a nongenetic model of insulin resistance). In addition, the effect of pioglitazone (3, 10 and 30 mg/kg p.o.) on diet-induced changes in body weight, plasma glucose, insulin, triglyceride and total cholesterol levels were also determined. The feeding of HFD for 4 weeks produced a significant increase in body weight, total fat pad weight, basal/fasting plasma glucose, insulin, basal triglyceride (TG) and total cholesterol (TC) levels in male rats. Furthermore, the rats fed HFD exhibited fasting hyperglycemia and hyperinsulinemia as well as enhanced glycemic response to exogenously administered glucose (2 g/kg p.o.) during an oral glucose tolerance test (OGTT) at the end of 4 weeks of dietary manipulation, indicating that the rats had developed insulin resistance and glucose intolerance. Treatment with pioglitazone (10 and 30 mg/kg p.o.) once daily for 2 weeks significantly diminished the elevated basal plasma insulin and TG levels in HFD-fed rats. In addition, a statistically significant reduction in TC level was observed only with the high dose of pioglitazone (30 mg/kg p.o.). However, pioglitazone had no significant effect on body weight, total fat pad weight and basal plasma glucose level. Pioglitazone (10 and 30 mg/kg p.o.) significantly reduced fasting hyperglycemia and reversed oral glucose intolerance to normal in HFD-fed rats compared with control normal rats. The above findings suggest that pioglitazone has potent insulin-sensitizing and lipid-lowering properties in a HFD-fed rat model. In conclusion, the present study demonstrates that the adult male rats on a HFD for 4 weeks exhibited the characteristic features of obesity, insulin resistance and glucose intolerance, namely increased body weight, increased total fat pad weight, mild basal/fasting hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia and impaired oral glucose tolerance, that closely resemble the human prediabetic obese insulin-resistant and glucose-intolerant state. Further treatment with pioglitazone once daily for 2 weeks significantly ameliorated changes in basal plasma insulin, TG and TC, and reversed oral glucose intolerance to normal in HFD-fed rats, suggesting its potential in the treatment of insulin resistance and glucose intolerance associated with abnormal lipid metabolism. |
---|---|
AbstractList | The present study was undertaken to determine the effect of pioglitazone (3, 10 and 30 mg/kg p.o.), an insulin sensitizer, on glucose intolerance in high fat diet- (HFD) fed rats (a nongenetic model of insulin resistance). In addition, the effect of pioglitazone (3, 10 and 30 mg/kg p.o.) on diet-induced changes in body weight, plasma glucose, insulin, triglyceride and total cholesterol levels were also determined. The feeding of HFD for 4 weeks produced a significant increase in body weight, total fat pad weight, basal/fasting plasma glucose, insulin, basal triglyceride (TG) and total cholesterol (TC) levels in male rats. Furthermore, the rats fed HFD exhibited fasting hyperglycemia and hyperinsulinemia as well as enhanced glycemic response to exogenously administered glucose (2 g/kg p.o.) during an oral glucose tolerance test (OGTT) at the end of 4 weeks of dietary manipulation, indicating that the rats had developed insulin resistance and glucose intolerance. Treatment with pioglitazone (10 and 30 mg/kg p.o.) once daily for 2 weeks significantly diminished the elevated basal plasma insulin and TG levels in HFD-fed rats. In addition, a statistically significant reduction in TC level was observed only with the high dose of pioglitazone (30 mg/kg p.o.). However, pioglitazone had no significant effect on body weight, total fat pad weight and basal plasma glucose level. Pioglitazone (10 and 30 mg/kg p.o.) significantly reduced fasting hyperglycemia and reversed oral glucose intolerance to normal in HFD-fed rats compared with control normal rats. The above findings suggest that pioglitazone has potent insulin-sensitizing and lipid-lowering properties in a HFD-fed rat model. In conclusion, the present study demonstrates that the adult male rats on a HFD for 4 weeks exhibited the characteristic features of obesity, insulin resistance and glucose intolerance, namely increased body weight, increased total fat pad weight, mild basal/fasting hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia and impaired oral glucose tolerance, that closely resemble the human prediabetic obese insulin-resistant and glucose-intolerant state. Further treatment with pioglitazone once daily for 2 weeks significantly ameliorated changes in basal plasma insulin, TG and TC, and reversed oral glucose intolerance to normal in HFD-fed rats, suggesting its potential in the treatment of insulin resistance and glucose intolerance associated with abnormal lipid metabolism. |
Author | Kaul, C L Patole, P S Ramarao, P Srinivasan, K |
Author_xml | – sequence: 1 givenname: K surname: Srinivasan fullname: Srinivasan, K organization: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Punjab, India – sequence: 2 givenname: P S surname: Patole fullname: Patole, P S – sequence: 3 givenname: C L surname: Kaul fullname: Kaul, C L – sequence: 4 givenname: P surname: Ramarao fullname: Ramarao, P |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15319810$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j9tKxDAURfMw4lz0CwTJD7SenDSd9FEGb1AQRJ-HNDnpRHqj6Qjj19tBhQ3rYcO-rNmi6zti7EZAKqTSd61PESBLMU9VqqWQiAu2ArktEpBKLdk6xk8AFEqqS7acIQotYMXKN_qiMZqG957XzdH2kXjopr6h0XSWeHU6awh93YTJfM-1s80PoT5wbybuAk2JJ8dHM8UrduFNE-n6jxv28fjwvntOytenl919mVgpxZRoVJQ5qnRFZpuhBxBW4dY4Y3OydF6Jghxm2iAUThib5aRAOV2hrgBxw25_c4dj1ZLbD2NozXja_9_CH0TcUBA |
CitedBy_id | crossref_primary_10_4252_wjsc_v14_i5_330 crossref_primary_10_1007_s00044_014_1269_5 crossref_primary_10_3889_oamjms_2023_11780 crossref_primary_10_1080_13813455_2021_1888302 crossref_primary_10_1146_annurev_nutr_012809_104755 crossref_primary_10_1111_j_1750_3841_2008_00958_x crossref_primary_10_1002_ptr_5392 crossref_primary_10_1074_jbc_C116_732990 crossref_primary_10_1371_journal_pone_0045638 crossref_primary_10_1016_j_lfs_2021_119624 crossref_primary_10_1080_02713680701593702 crossref_primary_10_1016_j_phrs_2015_12_003 crossref_primary_10_1016_j_biopha_2018_08_073 crossref_primary_10_1016_j_mehy_2010_11_024 crossref_primary_10_1080_01635581_2012_630556 crossref_primary_10_1186_s12906_020_03087_z crossref_primary_10_1186_s12882_015_0041_5 crossref_primary_10_3390_nu9101123 crossref_primary_10_1007_s13105_011_0085_3 crossref_primary_10_3390_biomedicines7040076 crossref_primary_10_1016_S2221_6189_14_60029_9 crossref_primary_10_1016_j_ejphar_2010_09_066 crossref_primary_10_1080_13813455_2019_1628069 crossref_primary_10_1002_cbdv_202000019 crossref_primary_10_1088_1742_6596_1146_1_012011 crossref_primary_10_1016_j_bcp_2020_113948 crossref_primary_10_1007_s13205_020_02429_5 crossref_primary_10_1016_j_neuint_2010_04_003 crossref_primary_10_1016_j_lfs_2022_121151 crossref_primary_10_1016_j_intimp_2015_09_021 crossref_primary_10_1016_j_jff_2015_02_005 crossref_primary_10_1007_s13205_023_03784_9 crossref_primary_10_1080_07391102_2023_2274516 crossref_primary_10_1210_en_2014_1367 crossref_primary_10_1039_C6RA10774E crossref_primary_10_1016_j_etp_2010_12_009 crossref_primary_10_1002_nbm_1327 crossref_primary_10_1016_j_ejphar_2008_06_016 crossref_primary_10_1042_BJ20100414 crossref_primary_10_1016_j_biopha_2018_09_028 crossref_primary_10_1152_ajpregu_00323_2013 crossref_primary_10_1007_s11657_016_0284_1 crossref_primary_10_1258_ebm_2011_011032 crossref_primary_10_53879_id_55_10_11489 crossref_primary_10_1371_journal_pone_0110455 crossref_primary_10_1002_biof_1333 crossref_primary_10_1186_2251_6581_12_60 crossref_primary_10_1089_jmf_2007_634 crossref_primary_10_1039_C4FO00859F crossref_primary_10_1210_jc_2005_0223 crossref_primary_10_1016_j_heliyon_2024_e33505 crossref_primary_10_15212_CVIA_2023_0020 crossref_primary_10_3109_13880200903527736 crossref_primary_10_1016_j_bbr_2019_112359 crossref_primary_10_1016_j_jep_2012_11_002 crossref_primary_10_1155_2017_4962950 crossref_primary_10_1002_jcp_26300 crossref_primary_10_1007_s00125_007_0591_6 crossref_primary_10_1111_j_1464_410X_2009_08852_x crossref_primary_10_1016_j_ynstr_2016_05_001 crossref_primary_10_1186_1465_9921_8_90 crossref_primary_10_1371_journal_pone_0117516 crossref_primary_10_1371_journal_pone_0167131 crossref_primary_10_1080_16583655_2022_2159210 crossref_primary_10_1155_2016_2492107 crossref_primary_10_1186_s42269_019_0089_7 crossref_primary_10_1016_j_biopha_2021_111908 crossref_primary_10_1186_s13578_020_00465_5 crossref_primary_10_1515_abm_2020_0034 crossref_primary_10_1007_s00213_020_05502_2 crossref_primary_10_1152_ajpendo_00109_2006 crossref_primary_10_1016_j_biopha_2016_06_025 crossref_primary_10_2500_ajra_2010_24_3522 crossref_primary_10_1002_mnfr_201801401 crossref_primary_10_1016_j_pharep_2016_03_004 crossref_primary_10_1111_j_1476_5381_2010_00994_x crossref_primary_10_15740_HAS_AJHS_14_2_251_260 crossref_primary_10_1016_j_repbio_2020_05_004 crossref_primary_10_1016_j_biopha_2017_07_112 crossref_primary_10_1016_j_fct_2017_07_008 crossref_primary_10_1016_j_lfs_2006_07_018 crossref_primary_10_1155_2014_507197 crossref_primary_10_1007_s11010_016_2828_5 crossref_primary_10_1002_pros_21041 crossref_primary_10_1016_j_ejps_2021_106105 crossref_primary_10_1016_j_phrs_2005_05_004 crossref_primary_10_1155_2013_763125 crossref_primary_10_1002_jcb_22783 crossref_primary_10_1016_j_ejphar_2021_174418 crossref_primary_10_3389_fphar_2017_00251 crossref_primary_10_1016_j_cbi_2022_110039 crossref_primary_10_3889_MJMS_1857_5773_2009_0037 crossref_primary_10_1152_ajpcell_00315_2011 crossref_primary_10_1007_s00394_016_1317_7 crossref_primary_10_1016_j_jep_2015_12_002 crossref_primary_10_1016_S1875_5364_17_30033_X crossref_primary_10_2217_nnm_2021_0401 crossref_primary_10_1016_j_foodres_2019_03_055 crossref_primary_10_1515_JBCPP_2006_17_2_71 crossref_primary_10_1016_j_jep_2010_08_053 crossref_primary_10_1186_s12906_016_1203_0 crossref_primary_10_1002_cam4_521 crossref_primary_10_4236_fns_2022_133022 crossref_primary_10_1007_s00210_010_0511_z crossref_primary_10_1007_s10529_014_1617_z crossref_primary_10_1177_09731296241238852 crossref_primary_10_3390_life12111731 crossref_primary_10_1016_j_phymed_2013_03_003 crossref_primary_10_1155_2016_9704607 crossref_primary_10_1016_j_etap_2020_103577 crossref_primary_10_1021_acs_jnatprod_9b00205 crossref_primary_10_1007_s40618_016_0456_2 crossref_primary_10_1016_j_bioorg_2020_104556 crossref_primary_10_1097_HJH_0b013e32834d9efe crossref_primary_10_1016_j_ejphar_2011_01_015 crossref_primary_10_1080_13813455_2020_1772829 crossref_primary_10_3760_cma_j_issn_0366_6999_20140022 crossref_primary_10_1016_j_mcn_2010_08_001 crossref_primary_10_3390_metabo13070871 crossref_primary_10_1002_biof_1892 crossref_primary_10_1155_2019_6419509 crossref_primary_10_1155_2021_5585650 crossref_primary_10_1007_s00044_011_9764_4 crossref_primary_10_1016_j_biopha_2018_09_173 crossref_primary_10_1016_j_ejphar_2020_173721 crossref_primary_10_1016_j_foodchem_2011_10_052 crossref_primary_10_1002_ptr_4994 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1358/mf.2004.26.5.831322 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 15319810 |
Genre | Journal Article |
GroupedDBID | --- 123 53G ABJNI ALLSV ALMA_UNASSIGNED_HOLDINGS CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P HJY NPM P2P RJZ SJN Z7D |
ID | FETCH-LOGICAL-c331t-825e4deb8bea742f001c527adac6ece021521ed248a209d1ac46e505d8b28b022 |
ISSN | 0379-0355 |
IngestDate | Fri Feb 23 03:01:32 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c331t-825e4deb8bea742f001c527adac6ece021521ed248a209d1ac46e505d8b28b022 |
PMID | 15319810 |
ParticipantIDs | pubmed_primary_15319810 |
PublicationCentury | 2000 |
PublicationDate | 2004-06-01 |
PublicationDateYYYYMMDD | 2004-06-01 |
PublicationDate_xml | – month: 06 year: 2004 text: 2004-06-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Spain |
PublicationPlace_xml | – name: Spain |
PublicationTitle | Methods and findings in experimental and clinical pharmacology |
PublicationTitleAlternate | Methods Find Exp Clin Pharmacol |
PublicationYear | 2004 |
SSID | ssj0021535 |
Score | 2.0325384 |
Snippet | The present study was undertaken to determine the effect of pioglitazone (3, 10 and 30 mg/kg p.o.), an insulin sensitizer, on glucose intolerance in high fat... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 327 |
SubjectTerms | Animals Blood Glucose - drug effects Body Weight - drug effects Cholesterol - blood Dietary Fats - administration & dosage Dose-Response Relationship, Drug Glucose Intolerance Hypoglycemic Agents - therapeutic use Insulin - blood Male Rats Rats, Sprague-Dawley Thiazolidinediones - therapeutic use Triglycerides - blood |
Title | Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15319810 |
Volume | 26 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBbp-rKXsXW_uxY9jL60zmxZspXHUTbK1pbQpdC3IlmnEVji0LiF9m_YH72TZMUm68ZWMCaxgqP4vhyn033fEfIeikzlpYHEWJbjAqVgiUozSHTFhRoJYZVvyXJyWhyd8y8X4mIw-NmrWrpu9LC6u5dX8hCr4jW0q2PJ_odlVzfFC_ga7YtntDCe_8nGZ-CKKkI4GWvPp_Om_gFXngmAoSUei2n93Ulx39VBIcQpFO9b1eybKTSJxYgTUbDsR6knvq10UG_2m9quted0rR2AJ8RFXuWiU8Be5ei_uc2hG7UMKdZVOnWs3AR99NrlXb-qa5-LjiwIv_M0U1eq7jhoMTfBuxqqyMkqR0maByHe6G8DQ77Fleg5zzyoBPzm1HPhiAoz61fzQ1YMxVA6xUnW_zRaZjHzds6cW5GhWPbvo2tK23Fog2yU0nnLU5f5aRfvOOjLYeMvahWscG4f7pmZ7_YU7ra2XvFxy-QpedIuOOjHgJ5nZADzLbI3Dva6PaCTjoC3PKB7dNyz5HNyHCFGa0tbiNEexKi-dUcfYjhMHcQoQoxGiFEHsRfk_POnyeFR0jbgSKo8z5pEMgHcgJYaVMmZxZCmEqxURlUFVOB7ImdgGJeKpSOTqYoXgCG1kZpJjdHhS_Jojl_8mlAJTjhKmzRX3G0dywysxre65BxSSN-QV-EpXS6CysplfH5v_ziyTR53oHtHNi3-rWEHY8RG73rj_QLaxWSh |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reversal+of+glucose+intolerance+by+by+pioglitazone+in+high+fat+diet-fed+rats&rft.jtitle=Methods+and+findings+in+experimental+and+clinical+pharmacology&rft.au=Srinivasan%2C+K&rft.au=Patole%2C+P+S&rft.au=Kaul%2C+C+L&rft.au=Ramarao%2C+P&rft.date=2004-06-01&rft.issn=0379-0355&rft.volume=26&rft.issue=5&rft.spage=327&rft_id=info:doi/10.1358%2Fmf.2004.26.5.831322&rft_id=info%3Apmid%2F15319810&rft_id=info%3Apmid%2F15319810&rft.externalDocID=15319810 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0379-0355&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0379-0355&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0379-0355&client=summon |